Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Laboratorios Farmaceuticos Rovi, S.A.: Strengths and Weaknesses

Highlights: Laboratorios Farmaceuticos Rovi, S.A.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses: Laboratorios Farmaceuticos Rovi, S.A.
  • The company's enterprise value to sales, at 4 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Rating Financials

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Laboratorios Farmaceuticos Rovi, S.A. SectorSpain

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
359.96Cr
BBB
1,03100Cr
A
64TCr -
BBB
- -
45TCr
AA
-
35TCr
AA
29TCr
AAA
25TCr
A
23TCr
A
20TCr
A
18TCr
AA
Average 36.33TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ROVI Stock
  4. Ratings Laboratorios Farmaceuticos Rovi, S.A.